Saluda Medical
Saluda Medical, Inc. is a medical technology company focused on developing and commercializing innovative solutions for patients suffering from chronic pain. Their primary focus is on neurostimulation therapies, aiming to provide more effective and personalized pain relief. Saluda's technology seeks to disrupt the pain management market by removing guesswork and tailoring treatment to individual patient needs.
Short position
Saluda Medical (ASX:SLD) has 0.11% of its shares on issue reported as short positions as of 5 Oct 2026, or about 274,301 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.06 percentage points. SLD is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Saluda Medical (SLD) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in USD, the reporting currency
- Revenue
- 90.2MM (source: ASX (Markit))vs 70.4MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −149.6MM (source: ASX (Markit))vs −149.3MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (basic)
- n/avs n/a (FY25)
- Rev YoY
- +28.2%FY
- EPS YoY
- n/aFY
- ASX (Markit)
Summary of FY26 Consolidated Financial Statements, 10 Sep 2026
Saluda Medical reported revenue of $90.2 million for FY2026, up 28% from $70.4 million in FY2025, but its net loss widened slightly to $149.6 million (from $149.3 million). No dividend was declared. The company's auditor noted substantial doubt about its ability to continue as a going concern due to ongoing losses and cash used in operations.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- −165.9%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a (reports in USD)
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (USD); market cap is in AUD. Source: ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in USD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | 90.2MM (source: ASX (Markit)) | 70.4MM (source: ASX (Markit)) | 51.7MM (source: ASX (Markit)) | 22.2MM (source: ASX (Markit)) |
| NPAT | −149.6MM (source: ASX (Markit)) | −149.3MM (source: ASX (Markit)) | −97.8MM (source: ASX (Markit)) | −92.2MM (source: ASX (Markit)) |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- FY26 Consolidated Financial StatementsFinancial Report10 Sep 2026via asx_announcements
- FY26 Full Year ResultsFull Year Results28 Aug 2026via asx_announcements
- Preliminary Final ReportAnnual Results28 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- Insider Trading PolicyFinancial Report31 Dec 2025via crawler
- Continuous Disclosure PolicyFinancial Report31 Dec 2025via crawler
- Anti-Bribery Anti-Corruption PolicyFinancial Report31 Dec 2025via crawler
Showing 10 of 19 reports